文献速递肝病

α-1抗胰蛋白酶缺乏症肝病:表观遗传异质性调节突变同质性并与肥胖相关

Alpha-1 Antitrypsin Deficiency Liver Disease, Mutational Homogeneity Modulated by Epigenetic Heterogeneity With Links to Obesity.
PubMed 文献 · Hepatology · 2019-03-20

研究探讨DNA甲基化(5-甲基胞嘧啶)对α-1抗胰蛋白酶缺乏症(AATD)肝病异质性的贡献。对ZZ基因型早期AATD成人肝活检进行全基因组5mC模式分析,并与正常肝、肝硬化和肝细胞癌患者比较。发现AATD肝病相关基因存在显著基因组低甲基化,5mC改变呈局部性,患者虽突变同质但表观遗传景观不同,差异甲基化CpG与临床特征及性别特异性肝病进展相关。

要点

  • AATD肝病患者虽具有相同的ZZ基因突变,但表观遗传景观存在显著异质性。
  • AATD肝病中5mC改变呈局部性,在基因组广泛低甲基化背景上出现高甲基化。
  • 差异甲基化CpG与肝细胞变性和聚合物积累等AATD临床特征及性别特异性肝病进展相关。

核心结论

  • AATD肝病突变同质群体中存在分子表观遗传特征,为分层评估肝病风险提供线索。

研究设计与样本

  • 使用具有早期AATD且为ZZ基因型的成人肝活检组织,进行全基因组5mC模式分析。
  • 比较早期AATD患者之间以及来自多种病因的正常肝、肝硬化和肝细胞癌患者的DNA甲基化。
  • 将患者临床和人口学特征与5mC景观进行关联分析。

主要发现

  • 全局分析显示AATD肝病中影响肝癌、细胞周期和纤维化的基因存在显著基因组低甲基化。
  • 5mC改变呈局部性,高甲基化发生在基因组广泛5mC丢失的背景中。
  • AATD患者尽管突变同质,但表现出不同的表观遗传景观。
  • AATD患者间差异甲基化的CpG与肝细胞变性和聚合物积累等标志性临床特征相关。
  • 差异甲基化CpG进一步揭示与肝病进展的已知性别特异性效应的关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alpha-1 antitrypsin deficiency (AATD) liver disease is characterized by marked heterogeneity in presentation and progression, despite a common underlying gene mutation, strongly suggesting the involvement of other genetic and/or epigenetic modifiers. Variation in clinical phenotype has added to the challenge of detection, diagnosis, and testing of new therapies in patients with AATD. We examined the contribution of DNA methylation (5-methylcytosine [5mC]) to AATD liver disease heterogeneity because 5mC responds to environmental and genetic cues and its deregulation is a major driver of liver disease. Using liver biopsies from adults with early-stage AATD and the ZZ genotype, genome-wide 5mC patterns were interrogated. We compared DNA methylation among patients with early AATD, and among patients with normal liver, cirrhosis, and hepatocellular carcinoma derived from multiple etiologic exposures, and linked patient clinical/demographic features. Global analysis revealed significant genomic hypomethylation in AATD liver-impacting genes related to liver cancer, cell cycle, and fibrosis, as well as key regulatory molecules influencing growth, migration, and immune function. Further analysis indicated that 5mC changes are localized, with hypermethylation occurring within a background of genome-wide 5mC loss and with patients with AATD manifesting distinct epigenetic landscapes despite their mutational homogeneity. By integrating clinical data with 5mC landscapes, we observed that CpGs differentially methylated among patients with AATD disease are linked to hallmark clinical features of AATD (e.g., hepatocyte degeneration and polymer accumulation) and further reveal links to well-known sex-specific effects of liver disease progression. Conclusion: Our data reveal molecular epigenetic signatures within this mutationally homogeneous group that point to ways to stratify patients for liver disease risk.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Wang L, Marek GW, Hlady RA, et al. Alpha-1 Antitrypsin Deficiency Liver Disease, Mutational Homogeneity Modulated by Epigenetic Heterogeneity With Links to Obesity. Hepatology. 2019. PMID: 30681738. doi:10.1002/hep.30526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。